Ionis Pharmaceuticals IONS AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value
AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's afs and trading securities - unrealized loss position (<12 months) fair value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's AFS and trading securities - unrealized loss position (<12 months) fair value?
- Ionis Pharmaceuticals (IONS) reported AFS and trading securities - unrealized loss position (<12 months) fair value of $1.02B in Q1 2026.
- How has Ionis Pharmaceuticals's AFS and trading securities - unrealized loss position (<12 months) fair value changed year-over-year?
- Ionis Pharmaceuticals's AFS and trading securities - unrealized loss position (<12 months) fair value increased by 30.4% year-over-year, from $783.82M to $1.02B.